Although interleukin-6 (IL-6) is recognized for its role in the inflammatory cascade and its contribution to endothelial injury, coagulopathy, and thromboembolism [32], its blockade is considered a potential strategy to attenuate cytokine storms [33], we did not identify a statistically significant difference in mean IL-6 levels between the COVID-19 and non-COVID-19 groups, despite the observed correlation with fibrinogen. Here, IL6 is linked to Thromboembolism.